[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651904":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":10,"centralContacts":29,"locations":36,"responsibleParty":57,"collaborators":10,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":69,"maxAge":10,"enrollmentInfo":70,"targetDuration":10,"studyType":73,"phases":10,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":82,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"University Hospital, Toulouse","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients benefiting from a personalized prevention initiative",null,"patients benefiting from a personalized prevention initiative aimed at improving nutritional or physical health",[13,14,15],"Other: Scale development phase","Other: Beta testing phase","Other: Validation phase",[17,21,25],{"type":6,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"Scale development phase","Questionnaire administered to patients to develop the scale's items and group them into subscales.",[9],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"Beta testing phase","The scale will be administered to the patient in the form of a questionnaire for the testing phase.",[9],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Validation phase","The scale will be administered to patients in the form of questionnaires for the validation phase.",[9],[30],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},"Jason SHOURICK, MD","CONTACT","05 61 14 56 23","+33","shourick.j@chu-toulouse.fr",[37],{"facility":38,"status":10,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Service d'Epidémiologie Clinique et de Santé Publique CHU de Toulouse, Pôle Santé Publique et Médecine Sociale Faculté de Médecine, 37 allées Jules Guesde","Toulouse","Oui","31000","France","FR",{"type":45,"coordinates":46},"Point",[47,48],1.44367,43.60426,{"lat":48,"lon":47},[51,55],{"name":52,"role":32,"phone":53,"phoneExt":10,"email":54},"Emeline Muller","0561778707","muller.E@chu-toulouse.Fr",{"name":56,"role":32,"phone":10,"phoneExt":10,"email":54},"MULLER",{"type":58,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100651904","development-and-validation-of-a-scale-of-propensity-for-change-in-chronic-disease-prevention-100651904",false,"NCT07765797","Development and Validation of a Scale of Propensity for Change in Chronic Disease Prevention","Development and Validation of a Propensity-to-change Scale in the Field of Chronic Disease Prevention: the ProChange Scale","ProChange","Inclusion Criteria:\n\n* Participant receiving a personalized prevention intervention through the frailty assessment day-hospital program, the Atherosclerosis Detection and Prevention Center (CDPA), or the Salutance program,\n* Participant who has received prevention advice aimed at improving their health in at least one of the following two areas: nutrition or physical activity,\n* Participant aged 45 or older (we are targeting a middle-aged to older population, as this group is the primary target for cardiovascular prevention initiatives and efforts to prevent pathological aging),\n\nExclusion Criteria:\n\n* Participant unable to improve their lifestyle, according to the scales used in the study (participant with a maximum score on the ONAPS-PAQ scale and the food frequency score),\n* Participant without a postal or email address,\n* Participant with a life expectancy of less than 5 years.",true,"ALL","45 Years",{"count":71,"type":72},290,"ESTIMATED","OBSERVATIONAL","Modifiable risk factors are estimated to account for 70% of cardiovascular diseases, 40% of Alzheimer's-type dementias, and 50% of type 2 diabetes cases. Numerous trials have evaluated interventions aimed at modifying these risk factors, whether through the promotion of healthy lifestyle choices (diet, physical activity, etc.) or specific activities (cognitive training, etc.). However, these trials have yielded inconsistent or modest results, potentially due to a failure to adopt the recommended lifestyle changes. To better tailor prevention interventions, it is therefore essential to have scales available that measure the barriers to and facilitators of lifestyle change.\n\nThe aim of this study is to develop and validate a Patient-Reported Outcome Measure (PROM) to assess the barriers to and facilitators of change following participation in a prevention program. The scale will be structured into three sub-scales (capability, opportunity, and motivation), administered one month after the prevention activity, and will distinguish between the adoption of new habits and the abandonment of existing ones.",[76,77],"Atheroscleroses","Geriatric",[79,80,81],"prevention","gériatrics","risk factors","NOT_YET_RECRUITING","2026-08-10",{"date":85,"type":86},"2026-08-14","ACTUAL",{"date":88,"type":72},"2026-09-01",{"date":90,"type":72},"2028-06-01",{"name":5,"class":6},1]